Another tested drug, Zileuton, is a selective inhibitor of 5-LOX, which is a key enzyme in the biosynthesis of the leukotrienes and has been implicated in central nervous system (CNS) disorders such as Alzheimer’s disease and acute ischemic stroke [31,32]. The gene discussed is ALOX5; the disease is early-onset autosomal dominant Alzheimer disease.